DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Damoctocog alfa pegol
Damoctocog alfa pegol
Justification
Active Data Protection Period Register of Innovative Drugs
Stembook 2018.Pdf
Hemophilia Treatment: Factors to Consider
(INN) for Biological and Biotechnological Substances
EHL FVIII Regimens for the Management of Hemophilia A
WFH Treatment Guidelines 3Ed Chapter 3 Laboratory
Nye Legemidler Som Ikke Har Markedsføringstillatelse for Legemidler Oppført På Listen Gjelder Retningslinjens Vilkår Uavhengig Av Indikasjon for Bruken
Covering Gene Therapy, Somatic Cell Therapy), and Recombinant Proteins Other Than Monoclonal Antibodies
11-14 February 2019 PRAC Meeting Minutes
Book of Abstracts, GTH, Bremen 2020;
Illuminating the Role of Shared Decision-Making As the Hemophilia a Management Landscape Continues to Evolve: Progress in Practice
Essential List of Medicinal Products for Rare Diseases: Recommendations from the Irdirc Rare Disease Treatment Access Working Group William A
Novel Treatments in Haemophilia and Other Bleeding Disorders: a Periodic EHC Review
Jivi, INN- Damoctocog Alfa Pegol
Committee for Medicinal Products for Human Use (CHMP) Agenda for the Meeting on 14-17 October 2019 Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
2018 FDA Approvals Summary BLA, NDA, & Tentative Approvals Key Drug-Device Supplements
Top View
Pipeline Drug List Drug Information Pharmacist
Bedfordshire, Luton and Milton Keynes CCG High Cost Drugs
Monitoring International Trends
ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
Decreased Bleeding Rates in Patients with Hemophilia a Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis
Products for Human
Extended Half-Life Factor VIII/Factor IX Products: Assay Discrepancies and Implications for Hemophilia Management
Sept-Oct 2018 Monitoring International Trends (Pdf)
Prevention and Management of Bleeding Episodes in Children with Hemophilia
Courtesy Translation – Only the German Version Is Legally Binding
October 2017 a View Into Upcoming Specialty and Traditional Drugs TABLE of CONTENTS
List Item PDCO Monthly Report of Opinions on Paediatric Investigation
Final Belgian List
Evolving Hemophilia Treatment Landscape
Hematology Drugs in the Pipeline
Emerging Insights in the Treatment of Patients with Haemophilia A
Novel Treatments in Haemophilia and Other Bleeding Disorders: a Periodic EHC Review 2021 Issue One
Jivi, INN-Damoctocog Alfa Pegol
Products for Human
(Jivi®) En Hemofilia A
(INN) for Biological and Biotechnological Substances
AR Annexes 2017 Collated
Peerview .Com /QUN900 Ensuring the Rapid Recognition and Optimal
January 2018 a View Into Upcoming Specialty and Traditional Drugs TABLE of CONTENTS
April 2018 a View Into Upcoming Specialty and Traditional Drugs TABLE of CONTENTS
Mrx CLINICAL ALERT
11Beffbcaff5d6995a07dec57393
Meds Entry Watch New Medicines Approved in 2018
List of Medicinal Products Under Additional Monitoring
New Developments in Haemophilia Treatment
Laboratory Testing in Hemophilia: Impact of Factor and Non-Factor Replacement Therapy on Coagulation Assays
Tenofovir Alafenamide
Novel Treatments in Haemophilia and Other Bleeding Disorders: a Periodic EHC Review 2020 Issue Two
Report on the Deliberation Results September 4, 2018 Pharmaceutical
2017/19 Pbr Excluded Drugs: Proposed GMMMG Advisory Position [Appendix 3]
Peerview.Com/CEV900 Implementing Care with Extended Half-Life Factor
Pbr Excluded Drugs List
Justification
Products for Human